Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohisa Saito

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Pharmacokinetics|July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2aTomohisa Saito, Satofumi Iida, Takehiko Kawanishi
Journal of Clinical Pharmacology|July 14, 2017
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and SimulationTomohisa Saito, Satofumi Iida, Kimio Terao, et al.
Biopharmaceutics & Drug Disposition|June 16, 2010
Prediction of human blood-to-plasma drug concentration ratioTakahide Uchimura, Motohiro Kato, Tomohisa Saito, et al.
Expert Review of Clinical Pharmacology|March 12, 2013
Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritisXiaoping Zhang, Peter N Morcos, Tomohisa Saito, et al.
The Journal of Pharmacy and Pharmacology|July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitorTomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Biological & Pharmaceutical Bulletin|August 5, 2009
A simulation study to evaluate limited sampling strategies to estimate area under the curve of drug concentration versus time following repetitive oral dosing: limited sampling model versus naive trapezoidal methodYuichiro Kayano, Isao Horiuchi, Yun-i Mori, et al.
Drug Research|August 14, 2018
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes MellitusSachiya Ikeda, Yasuki Takano, Dietmar Schwab, et al.
Clinical Pharmacokinetics|December 31, 2015
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an ExampleSheng Feng, Jun Shi, Neil Parrott, et al.
Drug Research|September 6, 2021
Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance HemodialysisMizuki Fukazawa-Shinotsuka, Tomohisa Saito, Masaichi Abe, et al.
Journal of the American Chemical Society|July 11, 2008
Reversible mechanochromic luminescence of [(C6F5Au)2(mu-1,4-diisocyanobenzene)]Hajime Ito, Tomohisa Saito, Naoya Oshima, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Pharmacokinetics|July 13, 2012
Population pharmacokinetic-pharmacodynamic modeling and simulation of platelet decrease induced by peg-interferon-alpha 2aTomohisa Saito, Satofumi Iida, Takehiko Kawanishi
Journal of Clinical Pharmacology|July 14, 2017
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and SimulationTomohisa Saito, Satofumi Iida, Kimio Terao, et al.
Biopharmaceutics & Drug Disposition|June 16, 2010
Prediction of human blood-to-plasma drug concentration ratioTakahide Uchimura, Motohiro Kato, Tomohisa Saito, et al.
Expert Review of Clinical Pharmacology|March 12, 2013
Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritisXiaoping Zhang, Peter N Morcos, Tomohisa Saito, et al.
The Journal of Pharmacy and Pharmacology|July 11, 2013
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitorTomohisa Saito, Satofumi Iida, Masaichi Abe, et al.
Biological & Pharmaceutical Bulletin|August 5, 2009
A simulation study to evaluate limited sampling strategies to estimate area under the curve of drug concentration versus time following repetitive oral dosing: limited sampling model versus naive trapezoidal methodYuichiro Kayano, Isao Horiuchi, Yun-i Mori, et al.
Drug Research|August 14, 2018
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes MellitusSachiya Ikeda, Yasuki Takano, Dietmar Schwab, et al.
Clinical Pharmacokinetics|December 31, 2015
Combining 'Bottom-Up' and 'Top-Down' Methods to Assess Ethnic Difference in Clearance: Bitopertin as an ExampleSheng Feng, Jun Shi, Neil Parrott, et al.
Drug Research|September 6, 2021
Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance HemodialysisMizuki Fukazawa-Shinotsuka, Tomohisa Saito, Masaichi Abe, et al.
Journal of the American Chemical Society|July 11, 2008
Reversible mechanochromic luminescence of [(C6F5Au)2(mu-1,4-diisocyanobenzene)]Hajime Ito, Tomohisa Saito, Naoya Oshima, et al.
Pageof 3